Dual Assessment of Antidiabetic Efficacy and Adverse Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetic Swiss Albino Male Mice
Alzahrani, E., Aldhmash, B., Elnagar, D., Batis, M., Almutairi, M., Alqarni, A., Alqahtani, W., Almansour, M., Rady, A., Khan, A., Ateya, A. (2025). Dual Assessment of Antidiabetic Efficacy and Adverse Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetic Swiss Albino Male Mice. EKB Journal Management System, 56(13), 1025-1037. doi: 10.21608/ejvs.2025.434679.3213
Elham Alzahrani; Badr Aldhmash; Doaa M Elnagar; Mohamed Batis; Mukhallad Almutairi; Aisha H Alqarni; Wajdan S Alqahtani; Mansour Almansour; Ahmed Rady; Amjad Khan; Ahmed Ateya. "Dual Assessment of Antidiabetic Efficacy and Adverse Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetic Swiss Albino Male Mice". EKB Journal Management System, 56, 13, 2025, 1025-1037. doi: 10.21608/ejvs.2025.434679.3213
Alzahrani, E., Aldhmash, B., Elnagar, D., Batis, M., Almutairi, M., Alqarni, A., Alqahtani, W., Almansour, M., Rady, A., Khan, A., Ateya, A. (2025). 'Dual Assessment of Antidiabetic Efficacy and Adverse Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetic Swiss Albino Male Mice', EKB Journal Management System, 56(13), pp. 1025-1037. doi: 10.21608/ejvs.2025.434679.3213
Alzahrani, E., Aldhmash, B., Elnagar, D., Batis, M., Almutairi, M., Alqarni, A., Alqahtani, W., Almansour, M., Rady, A., Khan, A., Ateya, A. Dual Assessment of Antidiabetic Efficacy and Adverse Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetic Swiss Albino Male Mice. EKB Journal Management System, 2025; 56(13): 1025-1037. doi: 10.21608/ejvs.2025.434679.3213

Dual Assessment of Antidiabetic Efficacy and Adverse Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetic Swiss Albino Male Mice

Egyptian Journal of Veterinary Sciences
Volume 56, Issue 13, December 2025, Pages 1025-1037    PDF (1.1 M)
Document Type: Original Article
DOI: 10.21608/ejvs.2025.434679.3213
Authors
Elham Alzahrani1; Badr Aldhmash1; Doaa M Elnagar1; Mohamed Batis2; Mukhallad Almutairi1; Aisha H Alqarni1; Wajdan S Alqahtani1; Mansour Almansour1; Ahmed Rady1; Amjad Khan3; Ahmed Ateya* 4
11 Zoology department, college of Science, King Saud University ,Riyadh, Saudi Arabia
22 Family and community medicine department, college of medicine, King Saud University ,Riyadh, Saudi Arabia
33 Kangbuk Samsung Hospital, Samsung Medical Centre, School of Medicine, Sungkyunkwan University (SKKU), Seoul, Korea
4Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.
Abstract
Semaglutide (S) is a GLP-1 receptor agonist; Tirzepatide (T) has dual GLP-1/GIP receptor agonism. This research compared their therapeutic effects and adverse reactions in a type 2 diabetes mellitus (T2DM) mouse model. Body weight, blood glucose, lipid profile, insulin, and IGF1 were estimated, as well as histopathological examination and gene expression. S and T independently led to prominent body weight reduction in diabetic mice, as well as enhancements of glucose and lipid profiles. However, histological examination showed that pancreas hemorrhage and intestine ulceration appeared after treatment. Immunohistochemistry and RT-PCR analysis revealed that insulin and glucagon expression were partially restored, CYP2E1 was over-expressed at a lower level after therapy. In conclusion, Semaglutide and Tirzepatide showed similar metabolic advantages; however, they caused significant changes in intestine and pancreatic structure, emphasizing the necessity for careful assessment over the long term.
Keywords
Semaglutide; Tirzepatide, Type 2 Diabetes, Swiss Albino Mice, Adverse Effects, GLP-1, GIP
Statistics
Article View: 1